Multiple Sclerosis Studies
If you think you may qualify for one of these studies, please contact CNI’s Research Department at 303-806-7423.
CHORDS: A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
The purpose of this study is to see if ocrelizumab (study drug) will stabilize, or potentially improve, the signs and symptoms of people with relapsing remitting MS. Researchers also want to find out if Ocrelizumab is safe and tolerable. Ocrelizumab is a type of drug called a monoclonal antibody. Monoclonal antibodies act like your body’s immune system and attach to certain cells in order to attack germs and other illnesses in your body. Ocrelizumab attaches to certain types of cells (B cells) that are thought to play a role in MS.
Eligibility and information – Closed to enrollment
Principal Investigator: Allen Bowling, MD, PhD